Monday June 24, 2019

Eat Walnuts to Ward off Diabetes Risk

Previous studies have showed that consuming half a cup of walnut per day may help protect the digestive system

0
//
Eat Walnuts to Ward off Diabetes Risk
Eat Walnuts to Ward off Diabetes Risk. Pixabay

Consuming walnuts — rich in antioxidants — may nearly halve the risk of developing Type-2 diabetes compared to those who do not eat nuts, finds a study representing more than 34,000 adults.

The findings showed doubling walnut consumption (or eating 3 tablespoons) was associated with a 47 per cent lower prevalence of Type-2 diabetes.

“The strong connection between walnut consumers and lower prevalence of Type-2 diabetes is additional justification for including walnuts in the diet. Other research has shown that walnuts may also be beneficial for cognitive function and heart health,” said Lenore Arab from the University of California, Los Angeles (UCLA).

For the study, the team looked at 34,121 adults aged 18-85 years who were asked about their dietary intake as well as if they had been diagnosed with diabetes or if they were taking medications for diabetes.

walnut
representational image. Pixabay

Individuals were also assessed for diabetes using common laboratory measurements including fasting plasma glucose and haemoglobin A1c.

Those who reported consuming walnuts showed a lower risk for Type-2 diabetes compared to those who did not consume any nuts regardless of age, gender, race, education, BMI and amount of physical activity.

Walnuts are a rich source of recommended polyunsaturated fat (13 grams per ounce), and the only nuts that contain a significant amount of alpha-linolenic acid (ALA) — the plant-based omega-3 fatty acid (2.5 grams per one ounce). It also offers protein (4 grams per one ounce) and fibre (2 grams per one ounce).

Also Read: TB Vaccine May Help to Control Type-1 Diabetes, Says Study

Previous studies have showed that consuming half a cup of walnut per day may help protect the digestive system by increasing the amount of probiotic bacteria in the gut and warding off risks of heart and brain diseases as well as cancer. (IANS)

Next Story

Researchers Find Drug to Delay Type-1 Diabetes by Two Years

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine

0
Diabetes
Representational image. Pixabay

In a first, researchers have found that a treatment affecting the immune system effectively slowed the progression to clinical Type-1 diabetes in high risk individuals by two years or more.

“The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment,” said Lisa Spain, Project Scientist from US National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The study, involving treatment with an anti-CD3 monoclonal antibody (teplizumab), was conducted by Type 1 Diabetes TrialNet, an international collaboration aimed at discovering ways to delay or prevent Type-1 diabetes.

Participants were randomly assigned to either the treatment group, which received a 14-day course of teplizumab, or the control group, which received a placebo.

All participants received glucose tolerance tests regularly until the study was completed, or until they developed clinical Type-1 diabetes – whichever came first.

During the trial, 72 per cent of the people in the control group developed clinical diabetes, compared to only 43 per cent of the teplizumab group.

diabetes
“Although Type-1 and Type-2 diabetes in parents are well-established risk factors for diabetes, we show that gestational diabetes mellitus may be a risk indicator for diabetes in the mother’s children before age 22,” . Pixabay

The median time for people in the control group to develop clinical diabetes was just over 24 months, while those who developed clinical diabetes in the treatment group had a median time of 48 months before progressing to diagnosis.

“The difference in outcomes was striking. This discovery is the first evidence we’ve seen that clinical Type-1 diabetes can be delayed with early preventive treatment,” Spain added.

Type-1 diabetes develops when the immune system’s T cells mistakenly destroy the body’s own insulin-producing beta cells.

Also Read- Cutting Sodium Intake May Prevent 94 Million Premature Deaths From CVD

Insulin is needed to convert glucose into energy. Teplizumab targets T cells to lessen the destruction of beta cells.

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine. (IANS)